This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
3 Reasons Growth Investors Will Love PJT Partners (PJT)
by Zacks Equity Research
PJT Partners (PJT) could produce exceptional returns because of its solid growth attributes.
PJT Partners (PJT) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PJT Partners (PJT) delivered earnings and revenue surprises of 69.49% and 37.04%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
PJT Partners (PJT) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
PJT Partners (PJT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MoneyGram Ties With E9Pay to Tap Korean Remittance Market
by Zacks Equity Research
MoneyGram (MGI) partners with E9Pay to provide its money transfer services in the burgeoning Korean remittance market.
Here's Why PJT Partners (PJT) Stock is Worth Betting on Now
by Zacks Equity Research
Given strong fundamentals and prospects, PJT Partners (PJT) stock is an attractive investment option at the moment.
Zacks.com featured highlights include: MagnaChip Semiconductor, PJT Partners, eXp World and Cumberland Pharmaceuticals
by Zacks Equity Research
Zacks.com featured highlights include: MagnaChip Semiconductor, PJT Partners, eXp World and Cumberland Pharmaceuticals
4 Top-Ranked Liquid Bets to Build a Successful Portfolio
by Zacks Equity Research
Here are four excellent liquid stocks that can contribute to making an outstanding portfolio for yield-seeking investors.
American Express (AXP) Q1 Earnings Beat Despite Coronavirus
by Zacks Equity Research
American Express' (AXP) Q1 earnings beat as the decline in revenues was more than compensated by a greater decrease in expenses.
The Zacks Analyst Blog Highlights: Cue Biopharma, PJT Partners, Avenue Therapeutics, SpartanNash and Gaia
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cue Biopharma, PJT Partners, Avenue Therapeutics, SpartanNash and Gaia
5 Top Small-Cap Stocks Braving Coronavirus Bloodbath
by Nalak Das
A handful of small-cap stocks have skyrocketed defying the coronavirus-induced market mayhem and extreme volatility.